Company intelligence / Profile preview

NovaSterilis

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

The company’s supercritical CO₂-based terminal sterilization process has been adopted in the tissue banking industry and approved by regulatory agencies in the US and Australia. Over half a million surgeries have used allograft tissues sterilized with this method. The technology preserves biological function while achieving high sterility assurance levels. Ongoing development aims to expand use into pharmaceutical and biotech manufacturing as an alternative to ethylene oxide.

Modalities: Device (sterilization equipment)Small molecule (sterilization of small molecule therapeutics)Biologic (sterilization of biologic materials)
Industry: Therapeutic Medical Devices

Partnerships

Collaborations with regenerative medicine manufacturers and contract research clients globallyAcademic institutions via grants

Beyond the preview

Go deeper on NovaSterilis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaSterilis.

Explore the full profile